Media Coverage
Aug 22, 2023
PreciseDx Begins Limited Rollout of 'Quantitative' Test for Grading Invasive Breast Cancer
See More
Aug 22, 2023
PreciseDx Begins Limited Rollout of 'Quantitative' Test for Grading Invasive Breast Cancer
See More
Media Coverage
Jul 24, 2023
AI-Powered Precision: Wayne Brinster and the Revolutionary Future of Disease Analysis at PreciseDx
See More
Jul 24, 2023
AI-Powered Precision: Wayne Brinster and the Revolutionary Future of Disease Analysis at PreciseDx
See More
Press Releases
Jun 27, 2023
PreciseDx Announces Ted Diehl as Vice President of Commercial Development
See More
Jun 27, 2023
PreciseDx Announces Ted Diehl as Vice President of Commercial Development
See More
Media Coverage
Jun 2, 2023
AI shows it can improve predictions for invasive breast cancer
See More
Jun 2, 2023
AI shows it can improve predictions for invasive breast cancer
See More
Press Releases
Mar 8, 2023
PreciseDx to Present on AI-enabled Breast Cancer Grade and Phenotyping Assay at United States and Canadian Academy of Pathology (USCAP) Annual Meeting
See More
Mar 8, 2023
PreciseDx to Present on AI-enabled Breast Cancer Grade and Phenotyping Assay at United States and Canadian Academy of Pathology (USCAP) Annual Meeting
See More
Media Coverage
Feb 20, 2023
New York and Florida Embrace AI-powered Oncology Tools
See More
Feb 20, 2023
New York and Florida Embrace AI-powered Oncology Tools
See More
Media Coverage
Feb 14, 2023
Filling a Global Gap: How technology can alleviate the impact of the global pathologist shortage
See More
Feb 14, 2023
Filling a Global Gap: How technology can alleviate the impact of the global pathologist shortage
See More
Press Releases
Feb 7, 2023
PreciseDx Receives New York State Approval for an AI-Enabled Breast Diagnostic
See More
Feb 7, 2023
PreciseDx Receives New York State Approval for an AI-Enabled Breast Diagnostic
See More
No results.
Contact us today to learn more about PreciseBreast.
